Lytix Biopharma AS

LYTIX · Oslo Børs · Healthcare

8.28NOK +0.2%last day

Price as of 2 October 2026

The price over the past year, with dividends: +16.6%

Performance

1 month

−1.4%

1 year

+16.6%

3 years, per year

+2.5%

5 years, per year

−10.7%

Largest fall, 3 years

−74.8%

Below the peak now

−55.5%

Volatility, 1 year

51.9%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

7.6

Dividend yield

0.0%

Return on equity

−109.2%

Net margin

–

Market value

66 m USD

Quality, value and trend

Where Lytix Biopharma stands against every Nordic stock today. 100 is best.

Quality63

Profitability and a sound balance sheet over time. Better than 63% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend33

The price development over the past year. Better than 33% of Nordic stocks.

Combined17

Quality, value and trend together. Better than 17% of Nordic stocks.

About Lytix Biopharma

Lytix Biopharma AS is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 14 employees.

Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis